Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes

Future Microbiology

Volumn 6, Issue 6, 2011, Pages 653-666

  Falagas, Matthew E ^a,b,c   Karageorgopoulos, Drosos E ^a   Nordmann, Patrice ^d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Associated French National Reference Center for Antibiotic Resistance: Carbapenemase producing Enterobacteriaceae   (France)

Author keywords

aminoglycosides; carbapenemases; combination drug therapy; fosfomycin; KPC; metallo lactamases; NDM; OXA 48; polymyxins

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; BETA LACTAMASE; CARBAPENEM; COLISTIN; FOSFOMYCIN; POLYMYXIN B; TIGECYCLINE;

ACINETOBACTER BAUMANNII; DISEASE ASSOCIATION; DRUG RESISTANCE; ENTEROBACTERIACEAE INFECTION; HOSPITAL INFECTION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

ENTEROBACTERIACEAE; NEGIBACTERIA;

EID: 79959803273     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.49     Document Type: Review

References (136)

1. Boucher HW, Talbot GH, Bradley JS et al.: Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009
2. Nordmann P, Cuzon G, Naas T: The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9, 228-236 (2009
3. Yong D, Toleman MA, Giske CG et al.: Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53, 5046-5054 (2009
4. Nordmann P, Poirel L, Toleman MA, Walsh TR: Does broad-spectrum β-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother. 66, 689-692 (2011
5. Cuzon G, Naas T, Truong H et al.: Worldwide diversity of Klebsiella pneumoniae that produce β-lactamase blaKPC-2 gene. Emerg. Infect. Dis. 16, 1349-1356 (2010
6. Sidjabat HE, Silveira FP, Potoski BA et al.: Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin. Infect. Dis. 49, 1736-1738 (2009
7. Walsh TR, Toleman MA, Poirel L, Nordmann P: Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18, 306-325 (2005
8. Marchaim D, Chopra T, Pogue JM et al.: Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in Metropolitan Detroit, Michigan. Antimicrob. Agents Chemother. 55, 593-599 (2011
9. Giakoupi P, Maltezou H, Polemis M, Pappa O, Saroglou G, Vatopoulos A: KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone. Euro Surveill. 14, (2009
10. Poirel L, Fortineau N, Nordmann P: International transfer of NDM-1-producing Klebsiella pneumoniae from Iraq to France. Antimicrob. Agents Chemother. 49,1608-1613 (2011
11. Navon-Venezia S, Leavitt A, Schwaber MJ et al.: First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob. Agents Chemother. 53, 818-820 (2009
12. Daikos GL, Petrikkos P, Psichogiou M et al.: Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53, 1868-1873 (2009
13. Zioga A, Miriagou V, Tzelepi E et al.: The ongoing challenge of acquired carbapenemases: a hospital outbreak of Klebsiella pneumoniae simultaneously producing VIM-1 and KPC-2. Int. J. Antimicrob. Agents 36, 190-191 (2010
14. Poirel L, Ros A, Carricajo A et al.: Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India. Antimicrob. Agents Chemother. 55, 447-448 (2011
15. Carrer A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P: Spread of OXA-48- positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob. Agents Chemother. 52, 2950-2954 (2008
16. Castanheira M, Desphande LM, Mathai D et al.: Early dissemination of NDM-1 and OXA-181 producing Enterobacteriaceae in Indian hospitals: report from the SENTRY antimicrobial surveillance program, 2006-2007. Antimicrob. Agents Chemother. 55, 1274-1278 (2011
17. Carrer A, Poirel L, Yilmaz M et al.: Spread of OXA-48 plasmid in Turkey and beyond. Antimicrob. Agents Chemother. 54, 1369-1373 (2010
18. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P: Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Western Europe, France. Antimicrob. Agents Chemother. 55(5), 2420-2423 (2011
19. Psichogiou M, Tassios PT, Avlamis A et al.: Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J. Antimicrob. Chemother. 61, 59-63 (2008
20. Smith Moland E, Hanson ND, Herrera Vl et al.: Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J. Antimicro. Chemother. 51, 711-714 (2003 (Pubitemid 36336168)
21. Pournaras S, Kristo I, Vrioni G et al.: Characteristics of meropenem heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing clinical isolates of K. pneumoniae. J. Clin. Microbiol. 48, 2601-2604 (2010
22. Kitchel B, Rasheed JK, Endimiani A et al.: Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54, 4201-4207 (2010
23. Yigit H, Queenan AM, Anderson GJ et al.: Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45, 1151-1161 (2001 (Pubitemid 32230996)
24. Tato M, Morosini M, Garcia L, Alberti S, Coque MT, Canton R: Carbapenem heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J. Clin. Microbiol. 48, 4089-4093 (2010
25. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicrobial susceptibility testing: twentieth informational supplement (June 2010 updateCLSI document M100-S20-U. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2010
26. European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 2011.
27. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH: Clinical outcomes of patients with Klebsiella pneumoniae K. pneumoniae carbapenemase-producing after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis. 64, 233-235 (2009
28. Falcone M, Mezzatesta ML, Perilli M et al.: Infections with VIM-1 metallo-β-lactamase-producing enterobacter cloacae and their correlation with clinical outcome. J. Clin. Microbiol. 47, 3514-3519 (2009
29. Mathers AJ, Cox HL, Bonatti H et al.: Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. Transpl. Infect. Dis. 11, 257-265 (2009
30. Bratu S, Mooty M, Nichani S et al.: Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49, 3018-3020 (2005 (Pubitemid 40917631)
31. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JI: Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54, 804-810 (2010
32. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP: Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29, 1099-1106 (2008
33. Bulik CC, Nicolau DP: In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54, 4112-4115 (2010
34. Falagas ME, Karageorgopoulos DE: Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375, 248-251 (2010
35. Panagiotakopoulou A, Daikos GL, Miriagou V, Loli A, Tzelepi E, Tzouvelekis LS: Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-β-lactamase. Int. J. Antimicrob. Agents 29, 360-362 (2007
36. Souli M, Konstantinidou E, Tzepi I et al.: Efficacy of carbapenems against a metallo- {b}-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model. J. Antimicrob. Chemother. 66(3), 611-617 (2011
37. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME: Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin. Microbiol. Infect. 11, 115-121 (2005 (Pubitemid 40259694)
38. Falagas ME, Kasiakou SK: Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 10, R27 (2006
39. Falagas ME, Rafailidis PI Matthaiou DK: Resistance to polymyxins: mechanisms, frequency and treatment options. Drug. Resist. Update 13, 132-138 (2010
40. Matthaiou DK, Michalopoulos A, Rafailidis PI et al.: Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case-control study. Crit. Care Med. 36, 807-811 (2008
41. Toth A, Damjanova I, Puskas E et al.: Emergence of a colistin-resistant KPC-2- producing Klebsiella pneumoniae ST258 clone in Hungary. Eur. J .Clin. Microbiol. Infect. Dis. 29, 765-769 (2010
42. Zarkotou O, Pournaras S, Voulgari E et al.: Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J. Clin. Microbiol. 48, 2271-2274 (2010
43. Falagas ME, Rafailidis PI, Ioannidou E et al.: Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int. J. Antimicrob. Agents 35, 194-199 (2010
44. Samonis G, Matthaiou DK, Kofteridis D, Maraki S, Falagas ME: In vitro susceptibility to various antibiotics of colistin-resistant Gram-negative bacterial isolates in a general tertiary hospital in Crete, Greece. Clin. Infect. Dis. 50, 1689-1691 (2010
45. Strenger V, Gschliesser T, Grisold A et al.: Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum β-lactamase-producing enterobacteria in hospitalised newborns. Int. J. Antimicrob. Agents 37, 67-69 (2011
46. Grylack L, Neugebauer D, Scanlon JW: Effects of oral antibiotics on stool flora and overall sensitivity patterns in an intensive care nursery. Pediatr. Res. 16, 509-511 (1982 (Pubitemid 12075317)
47. Elemam A, Rahimian J, Mandell W: Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin. Infect. Dis. 49, 271-274 (2009
48. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG: Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J. Clin. Microbiol. 47, 1611-1612 (2009
49. Urban C, Tiruvury H, Mariano N, Colon- Urban R, Rahal JJ: Polymyxin-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 55, 388-389 (2011
50. Li J, Rayner CR, Nation RL et al.: Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50, 2946-2950 (2006 (Pubitemid 44396396)
51. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D: Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 66(4), 946-947 (2011
52. Poudyal A, Howden BP, Bell JM et al.: In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62, 1311-1318 (2008
53. Lo-Ten-Foe JR, De Smet AM, Diederen BM, Kluytmans JA, Van Keulen PH: Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 51, 3726-3730 (2007 (Pubitemid 47519365)
54. Daikos GI, Jackson GG, Lolans VT, Livermore DM: Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J. Infect. Dis. 162, 414-420 (1990 (Pubitemid 20239957)
55. Groisman EA, Kayser J, Soncini FC: Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J. Bacteriol. 179, 7040-7045 (1997 (Pubitemid 27492489)
56. Nicas TI, Hancock RE: Alteration of susceptibility to EDTA, polymyxin B and gentamicin in Pseudomonas aeruginosa by divalent cation regulation of outer membrane protein H1. J. Gen. Microbiol. 129, 509-517 (1983 (Pubitemid 13186938)
57. Skiada A, Markogiannakis A, Plachouras D, Daikos GL: Adaptive resistance to cationic compounds in Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 37(3), 187-193 (2011
58. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA: Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect. Immun. 72, 7107-7114 (2004 (Pubitemid 39552380)
59. Llobet E, Tomas JM, Bengoechea JA: Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 154, 3877-3886 (2008
60. Li J, Coulthard K, Milne R et al.: Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52, 987-992 (2003 (Pubitemid 38008420)
61. Plachouras D, Karvanen M, Friberg LE et al.: Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 53, 3430-3436 (2009
62. Markou N, Markantonis SL, Dimitrakis E et al.: Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin. Ther. 30, 143-151 (2008 (Pubitemid 351834728)
63. Daikos GL, Skiada A, Pavleas J et al.: Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J. Chemother. 22, 175-178 (2010
64. Wallace SJ, Li J, Nation Rl et al.: Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob. Agents Chemother. 52, 1159-1161 (2008 (Pubitemid 351358406)
65. Falagas ME, Kasiakou SK: Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world. Antimicrob. Agents Chemother. 50, 2274-2275 (2006 (Pubitemid 43807566)
66. Hirsch EB, Tam VH: Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65, 1119-1125 (2010
67. Souli M, Galani I, Antoniadou A et al.: An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin. Infect. Dis. 50, 364-373 (2010
68. Souli M, Kontopidou FV, Papadomichelakis E, Galani I, Armaganidis A, Giamarellou H: Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek university hospital. Clin. Infect. Dis. 46, 847-854 (2008 (Pubitemid 351417185)
69. Kofteridis DP, Alexopoulou C, Valachis A et al.: Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case- control study. Clin. Infect. Dis. 51, 1238-1244 (2010
70. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME: Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin. Microbiol. Infect. 16, 1230-1236 (2010
71. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V: Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J. Antimicrob. Chemother. 65, 2645-2649 (2010
72. Castanheira M, Sader HS, Jones RN: Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb. Drug. Resist. 16, 61-65 (2010
73. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G: Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents 35, 240-243 (2010
74. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME: Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 62, 895-904 (2008
75. Bratu S, Landman D, George A, Salvani J, Quale J: Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City. J. Antimicrob. Chemother. 64, 278-283 (2009
76. Falagas ME, Karageorgopoulos DE, Dimopoulos G: Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr. Drug Metab. 10, 13-21 (2009
77. Nicasio AM, Crandon JL, Nicolau DP: In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53, 2756-2761 (2009
78. Gardiner D, Dukart G, Cooper A, Babinchak T: Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 Phase III clinical trials. Clin. Infect. Dis. 50, 229-238 (2010
79. Tarchini G: Tigecycline and bacteremia - the dangers of post hoc analysis of pooled data. Clin. Infect. Dis. 51, 867-868 (2010
80. Nguyen M, Eschenauer GA, Bryan M et al.: Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn. Microbiol. Infect. Dis. 67, 180-184 (2010
81. Freire AT, Melnyk V, Kim MJ et al.: Comparison of tigecycline with imipenem/ cilastatin for the treatment of hospital-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 68, 140-151 (2010
82. US FDA: FDA drug safety communication: increased risk of death with tygacil (Tigecycline) compared to other antibiotics used to treat similar infections. (2011-2012-2015
83. Poulakou G, Kontopidou FV, Paramythiotou E et al.: Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens. J. Infect. 58, 273-284 (2009
84. Anthony KB, Firshman NO, Linkin DR et al.: Clinical and microbiological outcomes of serious infection with multidrug resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46,567-570 (2008 (Pubitemid 351263497)
85. Livermore DM, Mushtaq S, Warner M et al.: Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66, 48-53 (2011
86. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM: Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 43, 727-737 (1999 (Pubitemid 29165732)
87. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al.: Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. Infect. Dis. 27, 439-443 (2008 (Pubitemid 351713066)
88. Daikos GK, Kosmidis JC, Hamilton- Miller JM, Brumfitt W: Amikacin in treatment of infections caused by Gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results. J.Infect. Dis. 134(Suppl.), S286-S290 (1976
89. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39, 650-655 (1995
90. Jackson GG, Riff LJ: Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J. Infect. Dis. 124(Suppl.), S185-S191 (1971
91. Layeux B, Taccone FS, Fagnoul D, Vincent JL, Jacobs F: Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 54, 4939-4941 (2010
92. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE: Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect. Dis. 10, 43-50 (2010
93. Endimiani A, Patel G, Hujer KM et al.: In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob. Agents Chemother. 54, 526-529 (2010
94. Oteo J, Orden B, Bautista V et al.: CTX-M- 15-producing urinary Escherichia coli O25β-ST131-phylogroup B2 has acquired resistance to fosfomycin. J. Antimicrob. Chemother. 64, 712-717 (2009
95. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI: Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis. 46, 1069-1077 (2008 (Pubitemid 351589875)
96. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME: Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34, 506-515 (2009
97. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI: Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47(9), 2850-2858 (2003 (Pubitemid 37040258)
98. Ellington MJ, Livermore DM, Pitt TL, Hall LM, Woodford N: Mutators among CTX-M β-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J. Antimicrob. Chemother 58, 848-852 (2006 (Pubitemid 44390964)
99. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM: In vitro activity of fosfomycin against Gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int. J. Antimicrob. Agents 22 (Suppl. 2), 53-59 (2003
100. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME: Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 16, 184-186 (2010
101. Kitchel B, Sundin DR, Patel JB: Regional dissemination of KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 53, 4511-4513 (2009
102. Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD: New Delhi metallo-β-lactamase from traveler returning to Canada. Emerg. Infect. Dis. 17(2), 242-244 (2011
103. Kahlmeter G: An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J. Antimicrob. Chemother. 51, 69-76 (2003 (Pubitemid 36163829)
104. Lerner SA, Price S, Kulkarni S: Microbiological studies of fosfomycin trometamol against urinary isolates in vitro. In: New Trends in Urinary Tract Infections: the Single-Dose Therapy. S Karger AG, Basel, Switzerland, 121-121 (1988
105. Ferrara A, Migliori GB, Piccioni PD, Grassi FA, Colombo ML, Grassi GG: Influence of experimental conditions on in vitro activity of fosfomycin trometamol and emergence of resistant variants. In: New Trends in Urinary Tract Infections: the Single-Dose Therapy. S Karger Pub, 269-269 (1988
106. Gobernado M, Santos M, Diosdado N, Perez F: The evolution of the sensitivity to fosfomycin over the past two years. Chemotherapy 23(Suppl. 1), 99-103 (1977 (Pubitemid 8015941)
107. Hendlin D, Celozzi E, Weissberger B, Foltz EL: Effect of fosfomycin on the fecal microflora of man. Chemotherapy 23(Suppl. 1), 117-126 (1977 (Pubitemid 8015944)
108. Aaron SD, Vandemheen KL, Ferris W et al.: Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366, 463-471 (2005 (Pubitemid 41111694)
109. Pournaras S, Vrioni G, Neou E et al.: Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob; Agents 37, 244-247 (2011
110. Elemam A, Rahimian J, Doymaz M: In vitro evaluation of antibiotic synergy for polymyxin β-resistant carbapenemase-producing Klebsiella pneumoniae. J. Clin. Microbiol. 48, 3558-3562 (2010
111. Naas T, Cuzon G, Babics A et al.: Endoscopy-associated transmission of carbapenem-resistant Klebsiella pneumoniae producing KPC-2 β-lactamase. J. Antimicrob. Chemother. 65, 1305-1306 (2010
112. Benenson S, Navon-Venezia S, Carmeli Y et al.: Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult. Successful treatment with gentamicin and colistin. Int. J. Infect. Dis. 13, E295-E298 (2009
113. Bratu S, Tolaney P, Karumudi U et al.: Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56, 128-132 (2005 (Pubitemid 41418346)
114. Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K: Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob. Agents Chemother. 53, 2133-2135 (2009
115. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL: In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella producing a KPC carbapenemase. Antimicrob. Agents Chemother. 55(4), 1420-1427 (2011
116. Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME: Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against MDR Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Presented at: 21st European Congress on Clinical Microbiology and Infectious Diseases, Milan, Italy, 7-10 May 2011.
117. Souli M, Galani I, Boukovalas S et al.: In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob. Agents Chemother. 55(5), 2395-2397 (2011
118. Yanagida C, Ito K, Komiya I, Horie T: Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. Chem. Biol. Interact. 148, 139-147 (2004 (Pubitemid 38987831)
119. Woodford N, Turton JF, Livermore DM: Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. DOI: 10.1111/j.1574-6976.2011.00268.x. (2011) (Epub ahead of print
120. Weintrob AC, Roediger MP, Barber M et al.: Natural history of colonization with Gram-negative multidrug-resistant organisms among hospitalized patients. Infect. Control. Hosp. Epidemiol. 31, 330-337 (2010
121. Poulou A, Spanakis N, Pournaras S et al.: Recurrent healthcare-associated community-onset infections due to Klebsiella pneumoniae producing VIM-1 metallo-β-lactamase. J. Antimicrob . Chemother. 65, 2538-2542 (2010
122. Poirel L, Hombrouck-Alet C, Freneaux C, Bernabeu S, Nordmann P: Global spread of New-Delhi metallo-β-lactamase 1. Lancet Infect Dis. 12, 832 (2010
123. Pitout JD, Nordmann P, Laupland KB, Poirel L: Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 56, 52-59 (2005 (Pubitemid 41418336)
124. Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P: Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 54, 4914-4916 (2010
125. Talbot GH: The antibiotic development pipeline for multidrug-resistant Gram-negative bacilli: current and future landscapes. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S55-S58 (2010
126. Bercot B, Poirel L, Nordmann P: Plasmid-mediated 16S rRNA methylases among extended-spectrum β-lactamase-producing Enterobacteriaceae isolates. Antimicrob. Agents Chemother. 5, 4526-4527 (2008
127. Bush K, Macielag MJ: New β-lactam antibiotics and β-lactamase inhibitors. Expert Opin. Ther. Pat 20, 1277-1293 (2010
128. Livermore DM, Mushtaq S, Warner M et al.: Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55, 390-394 (2011
129. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA: Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(1), 82-85 (2011
130. Endimiani A, Bethel C, Choudhary Y, Bonomo RA: In vitro activity of penem-1 in combination with β-lactams against blaKPC-possessing Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother 54, 1650-1651 (2010
131. Livermore DM, Mushtaq S, Warner M: Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J. Antimicrob. Chemother. 65, 2382-2395 (2010
132. Vaara M, Siikanen O, Apajalahti J, Frimodt-Moller N, Vaara T: Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J. Antimicrob. Chemother. 65, 942-945 (2010
133. Drulis-Kawa Z, Dorotkiewicz-Jach A: Liposomes as delivery systems for antibiotics. Int. J. Pharm. 387, 187-198 (2010
134. Michalopoulos A, Metaxas EI, Falagas ME: Aerosol delivery of antimicrobial agents during mechanical ventilation: current practice and perspectives. Curr. Drug Deliv. 8, 208-212 (2011
135. Carmeli Y, Akova M, Cornaglia G et al.: Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin. Microbiol. Infect. 16, 102-111 (2010
136. Sopirala MM, Mangino JE, Gebreyes WA et al.: Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 4678-4683 (2010).